|
May 12
|
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
The 3 Best Biotech Stocks to Buy in May 2024
|
|
May 4
|
Incyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 3
|
Q1 2024 Insight Enterprises Inc Earnings Call
|
|
May 2
|
Incyte to Present at Upcoming Investor Conference
|
|
May 1
|
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
|
|
Apr 30
|
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
|
|
Apr 30
|
Incyte misses quarterly profit on weak sales of lead drug
|
|
Apr 30
|
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Apr 30
|
Incyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in ...
|
|
Apr 30
|
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
|
|
Apr 26
|
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
|
|
Apr 25
|
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
|
|
Apr 24
|
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 23
|
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
|
|
Apr 23
|
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 23
|
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
|
|
Apr 15
|
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable
|
|
Apr 15
|
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
|
|
Apr 12
|
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
|